"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D04.210.500.247.808.197.244 D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 3 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 6 | 7 |
| 2000 | 1 | 5 | 6 |
| 2001 | 1 | 6 | 7 |
| 2002 | 2 | 6 | 8 |
| 2003 | 2 | 11 | 13 |
| 2004 | 1 | 8 | 9 |
| 2005 | 4 | 7 | 11 |
| 2006 | 6 | 7 | 13 |
| 2007 | 4 | 6 | 10 |
| 2008 | 7 | 4 | 11 |
| 2009 | 5 | 6 | 11 |
| 2010 | 2 | 10 | 12 |
| 2011 | 10 | 15 | 25 |
| 2012 | 4 | 15 | 19 |
| 2013 | 11 | 15 | 26 |
| 2014 | 12 | 14 | 26 |
| 2015 | 8 | 10 | 18 |
| 2016 | 11 | 14 | 25 |
| 2017 | 5 | 11 | 16 |
| 2018 | 8 | 9 | 17 |
| 2019 | 13 | 14 | 27 |
| 2020 | 5 | 10 | 15 |
| 2021 | 8 | 10 | 18 |
| 2022 | 1 | 23 | 24 |
| 2023 | 0 | 20 | 20 |
| 2024 | 4 | 13 | 17 |
| 2025 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Whole genome sequence analysis of low-density lipoprotein cholesterol across 246?K individuals. Genome Biol. 2025 Sep 09; 26(1):273.
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
-
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.
-
Laparoscopically confirmed endometriosis and midlife plasma markers of inflammation, cholesterol, and adipokines among participants in the Nurses' Health Study II. Maturitas. 2025 Sep; 200:108663.
-
Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease. Appl Health Econ Health Policy. 2025 Sep; 23(5):869-883.
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
-
Managing Hypercholesterolemia in Adults Older Than 75?years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus From the National Lipid Association and the American Geriatrics Society. J Am Geriatr Soc. 2025 Jun; 73(6):1674-1696.
-
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656.
-
Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. Am J Cardiovasc Drugs. 2025 May; 25(3):293-306.
-
Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry. Int J Cardiol. 2025 Feb 15; 421:132916.